Results 61 to 70 of about 13,156 (215)

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Comparative analysis for the presence of IgG anti-aquaporin-1 in patients with NMO-Spectrum disorders [PDF]

, 2016
Detection of IgG anti-Aquaporin-4 (AQP4) in serum of patients with Neuromyelitis optica syndrome disorders (NMOSD) has improved diagnosis of these processes and differentiation from Multiple sclerosis (MS).
Casado Chocán, José Luis, Díaz Sánchez, María, Echevarría Irusta, Miriam, Ramírez Lorca, Reposo, Suárez-Luna, Nela, Sánchez Gomar, Ismael, Toledo Aral, Juan José, Uclés Sánchez, Antonio José, Villadiego Luque, Francisco Javier   +8 more
core   +2 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Post-COVID Neuromyelitis Optica Spectrum Disorder

Journal of the College of Physicians and Surgeons Pakistan, 2021
After novel coronavirus pandemic that emerged from Wuhan, China in December 2019, several cases of inflammatory and immune-mediated disorders have been reported, thought to be triggered by SARS-CoV-2 infection. Neuromyelitis optica spectrum disorder (NMOSD) is one of the autoimmune demyelinating disorders, which is thought to be triggered by viral ...
Shumaila, Rafique, Areeba, Wasim, Tipu, Sultan, Arsalan, Ahmad   +3 more
openaire   +3 more sources

Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes

Biomedicines, 2019
Neuromyelitis optica spectrum disorder (NMOSD) and anti-myelin oligodendrocyte glycoprotein (anti-MOG) syndromes are immune-mediated inflammatory conditions of the central nervous system that frequently involve the optic nerves and the spinal cord ...
Marco A. Lana-Peixoto, Natália Talim
doaj   +1 more source

Study of the cytological features of bone marrow mesenchymal stem cells from patients with neuromyelitis optica. [PDF]

, 2019
Neuromyelitis optica (NMO) is a refractory autoimmune inflammatory disease of the central nervous system without an effective cure. Autologous bone marrow‑derived mesenchymal stem cells (BM‑MSCs) are considered to be promising therapeutic agents for this
Chang, Guoqiang, Ma, Li, Shi, Fu-Dong, Yan, Yaping, Yang, Chunsheng, Yang, Yang, Zhang, Guang-Xian   +6 more
core   +1 more source

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. [PDF]

, 2018
OBJECTIVE: We characterised the clinical course, treatment and outcomes in 59 patients with relapsing myelin oligodendrocyte glycoprotein (MOG) antibody-associated demyelination.
Australasian and New Zealand MOG Study Group Andrews, P, Barnett, Mh, Barton, J, Brilot, F, Broadley, S, Burrow, J, Butzkueven, H, Cairns, A, Calvert, S, Caruana, P, Chelakkadan, S, Clark, D, Dale, Rc, Fraser, C, Freeman, J, Fung, Vsc, Gill, D, Grattan-Smith, P, Gupta, S, Hardy, T, Henderson, Apd, Kothur, K, Lechner-Scott, J, Ling, S, Lopez, J, Malone, S, Marriott, M, Merheb, V, Mohammad, S, Nguyen, Tk, Nosadini, M, O'grady, G, Orr, C, Ouvrier, R, Parratt, J, Patrick, E, Pilli, D, Ramanathan, S, Reddel, Sw, Riminton, D, Riney, K, Rodriguez-Casero, V, Ryan, M, Scheffer, I, Shah, U, Shuey, N, Spooner, C, Subramanian, G, Tantsis, E, Tea, F, Thomas, T, Thompson, J, Troedson, C, Vucic, S, Ware, T, Webster, R, White, Ob, Yiannikas, C, Yiu, E, Zou, A.   +59 more
core   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Initial BMI effects on clinical presentation and prognosis in neuromyelitis optica spectrum disorder

Annals of Clinical and Translational Neurology, 2023
Objective To investigate the correlation among body mass index at onset, clinical features, and prognosis in patients with neuromyelitis optica spectrum disorder.
Wenqin Luo, Xiaofei Wang, Lingyao Kong, Hongxi Chen, Ziyan Shi, Hongyu Zhou   +5 more
doaj   +1 more source